v3.24.1.u1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash $ 190 $ 357
Accounts receivable 24 9
Employee advance 5
Inventory, short term 336
Net investment in leases, short term 103 101
Prepaid expenses and vendor deposits 206 325
Total current assets 528 1,128
Property and equipment, net 509 665
Right-to-use assets, net 412 705
Other assets:    
Inventory, long term 1,141
Net investment in leases, long term 17 120
Patents, net 288 307
Other assets 44 44
Total assets 1,798 4,110
Current liabilities:    
Accounts payable and accrued expenses, including $30 and $120 to related parties as of December 31, 2023 and 2022, respectively 4,116 2,852
Customer deposits 16
Deferred revenue, short term 5
Dividends payable 101 91
Lease liability, short term 349 313
Total current liabilities 4,582 3,261
Lease liability, long term 103 452
Total long-term liabilities 103 452
Total liabilities 4,685 3,713
Commitments and contingencies (Note 12)
Series C 9% Convertible Preferred Stock, $0.001 par value, $1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding; liquidation preference of $105 as of December 31, 2023 and 2022 105 105
Equity (Deficit):    
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B, 4,200 shares of Series C, 1,400 shares of Series D, 1,000 shares of Series E, 200,000 shares of Series F Preferred Stock. 105 shares of Series C outstanding as of December 31, 2023 and 2022 (see above)
Common stock, $0.001 par value, authorized 200,000,000 shares, 9,040,043 and 5,505,068 issued and outstanding as of December 31, 2023 and 2022, respectively 9 5
Additional paid in capital 241,988 216,282
Accumulated deficit (245,015) (215,974)
Total stockholders’ equity (deficit) attributable to BioSig Technologies, Inc. (3,018) 313
Non-controlling interest 26 (21)
Total equity (deficit) (2,992) 292
Total liabilities and equity (deficit) $ 1,798 $ 4,110

Source